enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. US FDA approves Pfizer's gene therapy for rare bleeding ... - AOL

    www.aol.com/news/us-fda-approves-pfizers-gene...

    (Reuters) -The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular ...

  3. Fidanacogene elaparvovec - Wikipedia

    en.wikipedia.org/wiki/Fidanacogene_elaparvovec

    In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...

  4. FDA approves Pfizer's first gene therapy for rare inherited ...

    www.aol.com/news/fda-approves-pfizer-first-gene...

    The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...

  5. Spark Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Spark_Therapeutics

    Fidanacogene elaparvovec, previously known by its study ID number SPK-9001, [12] is a gene therapy for the treatment of hemophilia B. It was developed by Spark in partnership with Pfizer . Fidanacogene elaparvovec is an adeno-associated viral vector which is designed to transfer a working copy of the Factor IX gene into the livers of patients ...

  6. Pfizer's gene therapy cuts hemophilia A bleeding rate in late ...

    www.aol.com/news/pfizers-hemophilia-gene-therapy...

    The data takes Pfizer one step closer to securing U.S. regulatory approval for a second gene therapy to treat hemophilia. Pfizer had received the Food and Drug Administration's nod for Beqvez as a ...

  7. P22phox - Wikipedia

    en.wikipedia.org/wiki/P22phox

    Cytochrome b is a heterodimer of two glycoproteins, gp91phox (also known as the heavy or β chain) and p22phox (the light or α chain).The heavy and light chains are closely associated in phagocytic cells, but while the expression of gp91phox is restricted to these cells, p22phox has been detected in many other cell types [1] and is able to function as a component of NAD(P)H oxidases. [2]

  8. Sangamo Therapeutics Stock Plunges As Pfizer Terminates ...

    www.aol.com/sangamo-therapeutics-stock-plunges...

    On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for ...

  9. Cytochrome b - Wikipedia

    en.wikipedia.org/wiki/Cytochrome_b

    Cytochrome b/b6 is an integral membrane protein of approximately 400 amino acid residues that probably has 8 transmembrane segments. In plants and cyanobacteria, cytochrome b6 consists of two protein subunits encoded by the petB and petD genes. Cytochrome b/b6 non-covalently binds two heme groups, known as b562 and b566.